Drug Profile
IPP 204106
Alternative Names: IPP-204106; IPP204106N; Nucant programme IPP-204106; polyplexed Nucant; poyplexed IPP-204106Latest Information Update: 04 Oct 2018
Price :
$50
*
At a glance
- Originator CNRS
- Developer CNRS; ImmuPharma
- Class Antineoplastics; Eye disorder therapies; Peptides; Skin disorder therapies
- Mechanism of Action Nucleolin inhibitors; Nucleophosmin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- No development reported Age-related macular degeneration; Diabetic retinopathy; Psoriasis; Wounds
Most Recent Events
- 25 Sep 2018 Incanthera signs Heads of Terms on a prospective licensing agreement with ImmuPharma for IPP 204106 for treatment of Cancer
- 28 Jan 2018 No recent reports of development identified for research development in Age-related-macular-degeneration in France (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Diabetic-retinopathy in France (Parenteral, Injection)